Department of Public Health, Hygée Centre, Lucien Neuwirth Cancer Institut, Saint Priest en Jarez.
Ann Oncol. 2014 Feb;25(2):500-4. doi: 10.1093/annonc/mdt553. Epub 2014 Jan 9.
Oral chemotherapies are increasingly prescribed. Yet wide variations in prescription practices and in monitoring of toxicity have been underlined despite existing guidelines. There is little recent information available as regard to these practices. We aimed to obtain exhaustive information on oral chemotherapy prescription practices and safety monitoring in French hospitals.
A cross-sectional multicentre survey was carried out to collect information on drug prescription, administration and surveillance: prescribing practices, coordination and monitoring of adherence, safety monitoring and side-effects occurrence prevention. Participants were a large sample of the French oncologists prescribing oral chemotherapy (20%).
One hundred and fifty-seven oncologists from 112 hospitals (public, comprehensive cancer centres and private) replied (23.7% of cancer hospitals). The majority (56.1%) of the prescriptions were hand-written on a blank sheet. Eighty-four physicians (53.5%) included dose information and 36 (23%) declared having no monitoring procedures for adherence. Only 84 responders (54%) provided education material at first prescription of oral chemotherapy in way to limit avoidable side-effects. Sixty-one (39%) responders stated that they recalled at least one serious adverse event in the previous year declared in their centre.
In this 2012 study, the majority of prescribers followed no standards in prescription writing, safety monitoring and toxicity prevention. The implementation of the international recommendations for oral chemotherapy administration should be considered as a top priority-for both prescribers and health authorities-as regards to the dynamic of development of these molecules and their potential side-effects.
越来越多的患者需要接受口服化疗。尽管存在相关指南，但处方实践和毒性监测方面仍存在广泛差异。关于这些实践的最新信息很少。我们旨在获取法国医院中口服化疗处方实践和安全性监测的详尽信息。
开展了一项横断面多中心调查，以收集有关药物处方、管理和监测的信息：处方实践、遵嘱协调和监测、安全性监测以及预防不良反应发生。参与者是法国开处口服化疗药物的肿瘤学家的大样本（20%）。
112 家医院（公立、综合性癌症中心和私立）的 157 名肿瘤学家（癌症医院的 23.7%）做出了回应。大部分（56.1%）处方是手写在空白纸上。84 名医生（53.5%）包括剂量信息，36 名（23%）医生表示没有监测遵嘱情况的程序。只有 84 名应答者（54%）在首次开处口服化疗药物时提供教育材料，以限制可避免的不良反应。61 名（39%）应答者表示，他们在过去一年中至少报告了在其中心发生的一起严重不良事件。
在这项 2012 年的研究中，大多数开处方者在处方书写、安全性监测和毒性预防方面没有遵循任何标准。考虑到这些分子的发展动态及其潜在的副作用，国际上关于口服化疗管理的建议的实施应被视为首要任务-无论是对开处方者还是卫生当局而言。
